Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Eribis Pharmaceuticals AB
AB
Active
Org 5567013221
Kåbovägen 10, 752 36
Uppsala
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2006 · 20 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Eribis Pharmaceuticals AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
SEK millions
No figures reported for this period.
EBITDA
SEK millions
0M
0M
0M
-1M
-1M
2015: 0M
0M
2015
2016: 0M
0M
2016
Income statement
SEK thousands
Item
2016
2015
Gross profit
—
—
Staff expenses
—
—
EBITDA
−6
−10
Depreciation & amort.
−0
−0
EBIT
−6
−10
Net financials
—
—
Profit before tax
−6
−10
Tax
−0
−0
Net profit
−6
−10
Balance sheet
SEK thousands
Item
2016
2015
Total assets
773
0
Equity
−611
−920
Long-term debt
0
0
Short-term debt
1 889
1 889
Total debt
1 889
1 889
Financial ratios
5-year trend
EBITDA margin (of gross profit)
<−999 %
This company
2015
2016
Equity ratio
−79,0 %
This company
38,2 %
Market median
This company
Market median
307% below market
2015
2016
Return on equity
—
This company
18,4 %
Market median
This company
Market median
2015
2016
Net profit margin (of gross profit)
<−999 %
This company
2015
2016
Asset turnover (of gross profit)
0,00×
This company
2015
2016
Debt / equity
—
This company
0,62×
Market median
This company
Market median
2015
2016
Annual reports & filings
Annual report 2016
Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
View
PDF
Annual report 2015
Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
View
PDF
More on Eribis Pharmaceuticals AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
